Colorectal Cancer Clinical Trials in Rochester, Minnesota

11 studies are recruiting for colorectal cancer in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic Rochester, Rochester, Minnesota

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   32 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06445062 on ClinicalTrials.gov

4. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

   The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Mayo Clinic Rochester, Rochester, Minnesota

   Locations

   29 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06562192 on ClinicalTrials.gov

5. A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

   The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   May Clinic Rochester, Rochester, Minnesota

   Locations

   39 in total

   Run by

   Ono Pharmaceutical Co., Ltd.

   See if you can join NCT06948448 on ClinicalTrials.gov

6. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

   Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug bei…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic-Rochester /ID# 273508, Rochester, Minnesota

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT07023289 on ClinicalTrials.gov

7. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

   Locations

   11 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

8. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

   The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Rochester, Rochester, Minnesota

   Locations

   12 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT06051695 on ClinicalTrials.gov

9. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

10. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

11. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov